1.Introduction Stroke remains the second leading cause of death and the third leading cause of death and disability combined worldwide,as indicated by disability-adjusted life-years(DALYs)lost[1].The highest burden of...1.Introduction Stroke remains the second leading cause of death and the third leading cause of death and disability combined worldwide,as indicated by disability-adjusted life-years(DALYs)lost[1].The highest burden of stroke disability is observed in developing countries of Asia and the stroke belt of the United States[2].Despite remarkable progress and advancements in evidence-based acute care therapies,such as intravenous thrombolysis and endovascular therapy,the burden of stroke remains significantly high[3].In 2023,a significant advancement in the treatment of ischemic stroke due to proximal intracranial arterial occlusion was marked by compelling evidence from several clinical trials that supported endovascular therapy,particularly for patients with a large ischemic core[4].Thus,endovascular therapy has entered a new era since the first clinical trial favoring endovascular therapy.However,more patients receiving endovascular therapy does not equal a better prognosis.Patients with stroke experience long-term dysfunction,and the percentage is much higher in patients with large ischemic cores.Therefore,numerous tasks must be performed to optimize acute stroke treatment strategies and improve rehabilitative care.展开更多
基金supported by the National Natural Science Foundation of China(82027802,82371470,and 82071468).
文摘1.Introduction Stroke remains the second leading cause of death and the third leading cause of death and disability combined worldwide,as indicated by disability-adjusted life-years(DALYs)lost[1].The highest burden of stroke disability is observed in developing countries of Asia and the stroke belt of the United States[2].Despite remarkable progress and advancements in evidence-based acute care therapies,such as intravenous thrombolysis and endovascular therapy,the burden of stroke remains significantly high[3].In 2023,a significant advancement in the treatment of ischemic stroke due to proximal intracranial arterial occlusion was marked by compelling evidence from several clinical trials that supported endovascular therapy,particularly for patients with a large ischemic core[4].Thus,endovascular therapy has entered a new era since the first clinical trial favoring endovascular therapy.However,more patients receiving endovascular therapy does not equal a better prognosis.Patients with stroke experience long-term dysfunction,and the percentage is much higher in patients with large ischemic cores.Therefore,numerous tasks must be performed to optimize acute stroke treatment strategies and improve rehabilitative care.
